- Home
- SDST vs OTLK Comparison
SDST vs OTLK Comparison
Compare SDST & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDST | OTLK |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 42.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SDST | OTLK |
|---|---|---|
| Price | $3.49 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $17.00 | $5.25 |
| AVG Volume (30 Days) | 113.6K | ★ 5.5M |
| Earning Date | 11-13-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,505,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $342.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $0.79 |
| 52 Week High | $70.25 | $3.39 |
Technical Indicators
Market Signals| Indicator | SDST | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 69.44 |
| Support Level | $3.06 | $1.51 |
| Resistance Level | $3.74 | $2.10 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 53.57 | 93.22 |
Price Performance
Historical ComparisonAbout SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.